AUROPHARMA.BOAUROPHARMA.BO
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +7.99% | +8.53% | +10.58% | +3.98% | +6.28% |
| Gross Profit Growth | +15.14% | +10.99% | +8.71% | +2.99% | -29.34% |
| EBITDA Growth | +16.15% | +6.43% | -0.30% | +3.31% | +14.05% |
| Operating Income Growth | +14.82% | +9.97% | +7.04% | -0.65% | -64.07% |
| Net Income Growth | +7.95% | -9.66% | -0.58% | -10.28% | +3.80% |
| EPS Growth | +9.12% | -9.23% | +0.32% | -9.50% | +4.36% |
| EPS Diluted Growth | +9.12% | -9.23% | +0.32% | -9.50% | +4.36% |
| Weighted Average Shares Growth | -1.07% | -0.48% | -0.90% | -0.86% | -0.52% |
| Weighted Average Shares Diluted Growth | -1.07% | -0.48% | -0.90% | -0.86% | -0.52% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -100.00% | -100.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | -100.00% | -100.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +16.10% | +0.00% | +19.61% | +0.00% | +9.36% |
| Inventory Growth | +12.38% | +0.00% | +7.50% | +0.00% | +7.29% |
| Asset Growth | +9.50% | +0.00% | +10.46% | +0.00% | +9.26% |
| Book Value per Share Growth | +10.73% | +10.07% | +10.41% | +10.32% | +14.08% |
| Debt Growth | +26.75% | +0.00% | +24.30% | +0.00% | -7.51% |
| R&D Expense Growth | +0.00% | +0.00% | +11.14% | +0.00% | +0.00% |
| SG&A Expenses Growth | +16.18% | +14.33% | +7.61% | +14.63% | +42.18% |